Lexicon Pharmaceuticals LXRX Payments to Acquire Investments
Payments to Acquire Investments at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInvestments.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's payments to acquire investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's payments to acquire investments?
- Lexicon Pharmaceuticals (LXRX) reported payments to acquire investments of $105.96M in Q1 2026.
- How has Lexicon Pharmaceuticals's payments to acquire investments changed year-over-year?
- Lexicon Pharmaceuticals's payments to acquire investments increased by 63.1% year-over-year, from $64.97M to $105.96M.
- What is the long-term trend for Lexicon Pharmaceuticals's payments to acquire investments?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's payments to acquire investments has grown at a 42.1% compound annual growth rate (CAGR), from $34.26M to $139.84M.
- What does payments to acquire investments mean?
- This reflects the cash used to purchase financial assets, such as marketable securities or other investment instruments. It indicates how the company allocates its excess cash reserves to generate returns or manage liquidity. High levels of investment activity suggest a focus on treasury management and capital preservation.